RHHVF ROCHE HOLDINGS AG
- 277.135
- -1.269-0.46%
ROCHE HOLDINGS AG News
Roche's Vabysmo Gets CHMP Recommendation for Third Indication Retinal Vein Occlusion (RVO)
Citi Maintains ROCHE HOLDINGS AG(RHHVF.US) With Buy Rating, Raises Target Price to $375.46
Citi analyst Peter Verdult maintains $ROCHE HOLDINGS AG(RHHVF.US)$ with a buy rating, and adjusts the target price from $374.93 to $375.46.According to TipRanks data, the analyst has a success rate of
Roche Launches New Analytical Units for Cobas Pro Integrated Solutions Delivering Greater Efficiency and Capacity to Laboratories
Roche Launches New Highly-sensitive Test to More Easily Diagnose Patients Who May Have B-cell Lymphoma
A Quick Look at Today's Ratings for ROCHE HOLDINGS AG(RHHVF.US), With a Forecast Between $234.18 to $267.64
On Jun 18, major Wall Street analysts update their ratings for $ROCHE HOLDINGS AG(RHHVF.US)$, with price targets ranging from $234.18 to $267.64.Goldman Sachs analyst James Quigley maintains with a se
Roche's VENTANA DP 200 Digital System Approved For Diagnostic Use By FDA
The solution, which includes the VENTANA DP 200 slide scanner, Roche's digital pathology workflow software and a display, is now cleared to aid in clinical diagnosis, enabling pathologists to diagnose
A Quick Look at Today's Ratings for ROCHE HOLDINGS AG(RHHVF.US), With a Forecast Between $235.74 to $264.93
On Jun 17, major Wall Street analysts update their ratings for $ROCHE HOLDINGS AG(RHHVF.US)$, with price targets ranging from $235.74 to $264.93.Goldman Sachs analyst James Quigley maintains with a se
Reported Saturday, Genentech's Phase III STARGLO Study Shows Columvi Increases Survival For Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma
– The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columv
Roche's Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Bernstein Initiates ROCHE HOLDINGS AG(RHHVF.US) With Buy Rating, Announces Target Price $341.27
Bernstein analyst Justin Smith initiates coverage on $ROCHE HOLDINGS AG(RHHVF.US)$ with a buy rating, and sets the target price at $341.27.According to TipRanks data, the analyst has a success rate of
Five-year Data for Genentech's Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk
Goldman Sachs Initiates ROCHE HOLDINGS AG(RHHVF.US) With Sell Rating, Announces Target Price $263.41
Goldman Sachs analyst James Quigley initiates coverage on $ROCHE HOLDINGS AG(RHHVF.US)$ with a sell rating, and sets the target price at $263.41.According to TipRanks data, the analyst has a success r
Deutsche Numis Maintains ROCHE HOLDINGS AG(RHHVF.US) With Hold Rating, Raises Target Price to $239.97
Deutsche Numis analyst Emmanuel Papadakis maintains $ROCHE HOLDINGS AG(RHHVF.US)$ with a hold rating, and adjusts the target price from $238.72 to $239.97.According to TipRanks data, the analyst has a
Roche's Genentech Granted Priority Review By FDA For Inavolisib, An Investigational Oral Therapy, In Combination With Palbociclib (Ibrance) And Fulvestrant
– Priority Review recognizes the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options –– Additional analyses of INAVO120 will be presented in an
Reported Earlier, Roche And Hitachi High-Tech Extend 46-Year Partnership For Diagnostic Testing Advances
Renewed partnership combines best in class engineering capabilities with cutting edge science to accelerate the availability of new solutions for customers and patients worldwideUpcoming launches of t
Roche and Hitachi High-Tech Extend Their 46-year Partnership, Paving the Way for Further Breakthroughs in Diagnostic Testing
Deutsche Numis Maintains ROCHE HOLDINGS AG(RHHVF.US) With Hold Rating, Cuts Target Price to $234.67
Deutsche Numis analyst Emmanuel Papadakis maintains $ROCHE HOLDINGS AG(RHHVF.US)$ with a hold rating, and adjusts the target price from $235.05 to $234.67.According to TipRanks data, the analyst has a
Deutsche Numis Maintains ROCHE HOLDINGS AG(RHHVF.US) With Hold Rating, Maintains Target Price $235.05
Deutsche Numis analyst Emmanuel Papadakis maintains $ROCHE HOLDINGS AG(RHHVF.US)$ with a hold rating, and maintains the target price at $235.05.According to TipRanks data, the analyst has a success ra
Deutsche Numis Maintains ROCHE HOLDINGS AG(RHHVF.US) With Hold Rating, Cuts Target Price to $235
Deutsche Numis analyst Emmanuel Papadakis maintains $ROCHE HOLDINGS AG(RHHVF.US)$ with a hold rating, and adjusts the target price from $235.05 to $235.According to TipRanks data, the analyst has a su
FDA Grants Breakthrough Therapy Designation to Roche's Inavolisib for Advanced Hormone Receptor-positive, HER2-negative Breast Cancer With a PIK3CA Mutation
Analysis
Price Target
No Data
